SE378110B - - Google Patents

Info

Publication number
SE378110B
SE378110B SE7206645A SE664572A SE378110B SE 378110 B SE378110 B SE 378110B SE 7206645 A SE7206645 A SE 7206645A SE 664572 A SE664572 A SE 664572A SE 378110 B SE378110 B SE 378110B
Authority
SE
Sweden
Application number
SE7206645A
Inventor
R L Brattsand
K G Claeson
Af Ekenstam B Thuresson
B A Thalen
Original Assignee
Bofors Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bofors Ab filed Critical Bofors Ab
Priority to SE7206645A priority Critical patent/SE378110B/xx
Priority to ZA732956A priority patent/ZA732956B/xx
Priority to IL42154A priority patent/IL42154A/en
Priority to AU55252/73A priority patent/AU478324B2/en
Priority to GB2219573A priority patent/GB1428416A/en
Priority to DE2323216A priority patent/DE2323216C3/de
Priority to CY1012A priority patent/CY1012A/xx
Priority to US359913A priority patent/US3928326A/en
Priority to FI731543A priority patent/FI50711C/fi
Priority to DK277073A priority patent/DK133249C/da
Priority to FR7318126A priority patent/FR2185406B1/fr
Priority to BE131271A priority patent/BE799728A/xx
Priority to SU1918554A priority patent/SU468408A3/ru
Priority to CA171,781A priority patent/CA1003402A/en
Priority to NLAANVRAGE7306979,A priority patent/NL175917C/xx
Priority to JP5623473A priority patent/JPS547794B2/ja
Publication of SE378110B publication Critical patent/SE378110B/xx
Priority to US05/629,493 priority patent/US3996359A/en
Priority to US05/629,390 priority patent/US3992534A/en
Priority to KE2969A priority patent/KE2969A/xx
Priority to HK490/79A priority patent/HK49079A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
SE7206645A 1972-05-19 1972-05-19 SE378110B (mo)

Priority Applications (20)

Application Number Priority Date Filing Date Title
SE7206645A SE378110B (mo) 1972-05-19 1972-05-19
ZA732956A ZA732956B (en) 1972-05-19 1973-05-01 A process for the separation of stereoisomeric mixtures into their components and components obtained hereby
IL42154A IL42154A (en) 1972-05-19 1973-05-01 Process for the separation of stereoisomeric mixtures of 16a,17a-alkylidenedioxy-pregnane derivatives into their components and components obtained thereby
AU55252/73A AU478324B2 (en) 1972-05-19 1973-05-04 A process for the separation of stereoisomeric mixtures into their components and components obtained hereby
GB2219573A GB1428416A (en) 1972-05-19 1973-05-09 Process for the separation of stereoisomeric mixtures of steroid acetals into their components and components obtained thereby
DE2323216A DE2323216C3 (de) 1972-05-19 1973-05-09 Verfahren zur Auftrennung von Stereoisomerengemischen von Pregna-1,4dien-11 -ol-33-dionen
CY1012A CY1012A (en) 1972-05-19 1973-05-09 Process for the separation of stereoisomeric mixtures of steroid acetals into their components and components obtainned thereby
US359913A US3928326A (en) 1972-05-19 1973-05-14 Process for the separation of stereoisomeric mixtures into their components and components obtained hereby
FI731543A FI50711C (fi) 1972-05-19 1973-05-14 Menetelmä kortikosteroidien stereoisomeeriseosten jakamiseksi stereois omeerikomponenteikseen.
DK277073A DK133249C (da) 1972-05-19 1973-05-17 Fremgangsmade til opspaltning af stereoisomerblandinger af 16alfa,17alfa-alkylidendioxypregnan-11beta,21-diol-3,20-dioner
FR7318126A FR2185406B1 (mo) 1972-05-19 1973-05-18
BE131271A BE799728A (fr) 1972-05-19 1973-05-18 Procede pour la separation de steredoisomeres de certains steroides
SU1918554A SU468408A3 (ru) 1972-05-19 1973-05-18 Способ разделени стереоизомерных смесей
CA171,781A CA1003402A (en) 1972-05-19 1973-05-18 Process for the separation of steroisomeric mixtures into their components and components obtained hereby
NLAANVRAGE7306979,A NL175917C (nl) 1972-05-19 1973-05-18 Werkwijze voor het splitsen van isomere mengsels van steroiden, werkwijze voor het bereiden van een farmaceutisch preparaat en aldus verkregen gevormd farmaceutisch preparaat.
JP5623473A JPS547794B2 (mo) 1972-05-19 1973-05-19
US05/629,493 US3996359A (en) 1972-05-19 1975-11-06 Novel stereoisomeric component A of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steroid 21-acylates, compositions thereof, and method of treating therewith
US05/629,390 US3992534A (en) 1972-05-19 1975-11-06 Compositions and method of treating with component B of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steriods
KE2969A KE2969A (en) 1972-05-19 1979-06-20 A process for the separation of sterioisomeric mixtures of steroid acetalsinto, their components and components obtained thereby
HK490/79A HK49079A (en) 1972-05-19 1979-07-19 A process for the separation of stereoisomeric mixtures of steroid acetals into their components and components obtained thereby

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE7206645A SE378110B (mo) 1972-05-19 1972-05-19

Publications (1)

Publication Number Publication Date
SE378110B true SE378110B (mo) 1975-08-18

Family

ID=20269238

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7206645A SE378110B (mo) 1972-05-19 1972-05-19

Country Status (17)

Country Link
US (1) US3928326A (mo)
JP (1) JPS547794B2 (mo)
BE (1) BE799728A (mo)
CA (1) CA1003402A (mo)
CY (1) CY1012A (mo)
DE (1) DE2323216C3 (mo)
DK (1) DK133249C (mo)
FI (1) FI50711C (mo)
FR (1) FR2185406B1 (mo)
GB (1) GB1428416A (mo)
HK (1) HK49079A (mo)
IL (1) IL42154A (mo)
KE (1) KE2969A (mo)
NL (1) NL175917C (mo)
SE (1) SE378110B (mo)
SU (1) SU468408A3 (mo)
ZA (1) ZA732956B (mo)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404200A (en) * 1980-12-04 1983-09-13 Aktiebolaget Draco 4-Pregnene-derivatives, a process for their preparation, composition and method for the treatment of inflammatory conditions

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL188581C (nl) * 1974-07-15 1992-08-03 Akzo Nv Werkwijze voor het bereiden van 11beta-hydroxy-18-alkylestraanverbindingen.
ZA763131B (en) * 1975-05-27 1978-01-25 Syntex Inc Use of flunisolide to treat respiratory diseases
IT1196142B (it) * 1984-06-11 1988-11-10 Sicor Spa Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
SE8604059D0 (sv) * 1986-09-25 1986-09-25 Astra Pharma Prod A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
GR1001529B (el) * 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
SE9100341D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroids
NZ259596A (en) * 1993-01-08 1997-04-24 Astra Ab Sugar-substituted glucocorticosteroid and use in medicaments specific to the colon or ileum
DE19635498A1 (de) * 1996-09-03 1998-03-26 Byk Gulden Lomberg Chem Fab Verfahren zur Epimerenanreicherung
IT1291288B1 (it) 1997-04-30 1999-01-07 Farmabios Srl Processo per la preparazione di 16,17 acetali di derivati pregnanici con controllo della distribuzione epimerica al c-22.
US6266556B1 (en) 1998-04-27 2001-07-24 Beth Israel Deaconess Medical Center, Inc. Method and apparatus for recording an electroencephalogram during transcranial magnetic stimulation
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and medicaments comprising it for use in treating primary insomnia and in the manufacture of such medicaments
AR045536A1 (es) * 2003-08-29 2005-11-02 Ranbaxy Lab Ltd Inhibidores de la fosfodiesterasa tipo -iv
WO2005051931A2 (en) * 2003-11-26 2005-06-09 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
WO2005100356A1 (en) 2004-04-09 2005-10-27 Merck & Co., Inc. Inhibitors of akt activity
EP1888050B1 (en) 2005-05-17 2012-03-21 Merck Sharp & Dohme Ltd. cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
US20090221664A1 (en) 2005-10-19 2009-09-03 Abhijit Ray Pharmaceutical compositions of muscarinic receptor antagonists
AU2006305620A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
US20100029728A1 (en) * 2006-09-22 2010-02-04 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
CA2664247A1 (en) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-iv
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
SI2099442T1 (sl) 2006-12-26 2015-03-31 Pharmacyclics, Inc. Postopek uporabe inhibitorjev histon deacetilaze in spremljanje biomarkerjev v kombiniranjem zdravljenju
AR064777A1 (es) 2007-01-10 2009-04-22 Inst Di Reserche D Biolog Mole Indazoles sustituidos con amida como inhibidores de poli (adp- ribosa) polimerasa (parp)
US20080207659A1 (en) * 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
KR101568884B1 (ko) 2007-03-14 2015-11-12 랜박시 래보러터리스 리미티드 포스포디에스테라제 저해제로서 피라졸로 (３,４-ｂ) 피리딘 유도체
US20110130403A1 (en) * 2007-03-14 2011-06-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
ITMI20080645A1 (it) 2008-04-11 2009-10-12 Ind Chimica Srl Procedimento per la preparazione di budesonide
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
GB0900484D0 (en) 2009-01-13 2009-02-11 Angeletti P Ist Richerche Bio Therapeutic agent
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
ME01331B (me) * 2009-09-11 2013-12-20 Chiesi Farm Spa Derivati izoksazolidina
GB0916608D0 (en) 2009-09-22 2009-11-04 Angeletti P Ist Richerche Bio Therapeutic compounds
AU2010307198B9 (en) 2009-10-14 2014-02-13 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
JP2013518909A (ja) 2010-02-08 2013-05-23 キナゲン，インク． アロステリックキナーゼ阻害が関係する治療方法および組成物
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
JP6043285B2 (ja) 2010-08-02 2016-12-14 サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低分子干渉核酸（ｓｉＮＡ）を用いたカテニン（カドヘリン結合型タンパク質）β１（ＣＴＮＮＢ１）遺伝子発現のＲＮＡ干渉媒介性阻害
LT2606134T (lt) 2010-08-17 2019-07-25 Sirna Therapeutics, Inc. Hepatito b viruso (hbv) geno raiškos slopinimas, tarpininkaujant rnr interferencijai naudojant mažą interferuojančią nukleorūgštį (sina)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
EP2699568A1 (en) 2011-04-21 2014-02-26 Piramal Enterprises Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
AU2011376953B2 (en) 2011-09-13 2017-08-24 Pharmacyclics Llc Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3453762B1 (en) 2012-05-02 2021-04-21 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
BR112015003729A2 (pt) 2012-08-24 2018-06-05 Univ Texas composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente
US9155747B2 (en) * 2012-09-13 2015-10-13 Chiesi Farmaceutici S.P.A. Isoxazolidine derivatives
EP2900241B1 (en) 2012-09-28 2018-08-08 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
AU2013352568B2 (en) 2012-11-28 2019-09-19 Merck Sharp & Dohme Llc Compositions and methods for treating cancer
ES2707305T3 (es) 2012-12-20 2019-04-03 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de HDM2
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
EP3475275B1 (en) 2016-06-23 2024-04-10 Merck Sharp & Dohme LLC 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
SG10202104259RA (en) 2016-11-08 2021-06-29 Regeneron Pharma Steroids and protein-conjugates thereof
KR20200007905A (ko) 2017-05-18 2020-01-22 리제너론 파마슈티칼스 인코포레이티드 사이클로덱스트린 단백질 약물 접합체
EP3706805A2 (en) 2017-11-07 2020-09-16 Regeneron Pharmaceuticals, Inc. Hydrophilic linkers for antibody drug conjugates
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
MA50259A1 (fr) 2018-01-08 2021-07-29 Regeneron Pharma Stéroïdes et leurs conjugués-anticorps
CA3098453A1 (en) 2018-05-09 2019-11-14 Regeneron Pharmaceuticals, Inc. Anti-msr1 antibodies and methods of use thereof
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
US12552826B2 (en) 2018-08-07 2026-02-17 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US12173026B2 (en) 2018-08-07 2024-12-24 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2021126732A1 (en) 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Prmt5 inhibitors
CA3160153A1 (en) 2019-12-17 2021-06-24 Michelle Machacek Prmt5 inhibitors
EP4076459A4 (en) 2019-12-17 2023-12-20 Merck Sharp & Dohme LLC Prmt5 inhibitors
US12441730B2 (en) 2019-12-17 2025-10-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
AU2023336062A1 (en) 2022-09-02 2025-03-13 Merck Sharp & Dohme Llc Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
KR20250079227A (ko) 2022-10-25 2025-06-04 머크 샤프 앤드 돔 엘엘씨 엑사테칸-유래 adc 링커-페이로드, 제약 조성물, 및 그의 용도
AU2023397331A1 (en) 2022-12-14 2025-06-26 Merck Sharp & Dohme Llc Auristatin linker-payloads, pharmaceutical compositions, and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133940A (en) * 1956-04-10 1964-05-19 Glaxo Group Ltd Process for the separation of delta-1, 4-3-keto steroid compounds from mixtures thereof with other 3-keto steroids
US3197469A (en) * 1958-08-06 1965-07-27 Pharmaceutical Res Products In 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor
US3048581A (en) * 1960-04-25 1962-08-07 Olin Mathieson Acetals and ketals of 16, 17-dihydroxy steroids
US3128238A (en) * 1962-09-14 1964-04-07 Lilly Co Eli delta1-dehydrogenation of steroids by fermentation with actinoplanaceae

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404200A (en) * 1980-12-04 1983-09-13 Aktiebolaget Draco 4-Pregnene-derivatives, a process for their preparation, composition and method for the treatment of inflammatory conditions

Also Published As

Publication number Publication date
JPS4941379A (mo) 1974-04-18
NL175917C (nl) 1985-01-16
FI50711B (mo) 1976-03-01
NL7306979A (mo) 1973-11-21
FR2185406B1 (mo) 1976-12-31
GB1428416A (en) 1976-03-17
JPS547794B2 (mo) 1979-04-10
ZA732956B (en) 1974-04-24
CY1012A (en) 1979-11-23
BE799728A (fr) 1973-09-17
IL42154A (en) 1976-12-31
DK133249B (da) 1976-04-12
IL42154A0 (en) 1973-07-30
DE2323216B2 (de) 1977-11-03
NL175917B (nl) 1984-08-16
SU468408A3 (ru) 1975-04-25
DE2323216C3 (de) 1978-06-22
KE2969A (en) 1979-07-20
DE2323216A1 (de) 1973-11-29
AU5525273A (en) 1974-11-07
CA1003402A (en) 1977-01-11
DK133249C (da) 1976-09-13
US3928326A (en) 1975-12-23
FI50711C (fi) 1976-06-10
FR2185406A1 (mo) 1974-01-04
HK49079A (en) 1979-07-27

Similar Documents

Publication Publication Date Title
FR2185406B1 (mo)
JPS5047227A (mo)
JPS518437B2 (mo)
JPS48103487U (mo)
JPS48104080A (mo)
AU465433B2 (mo)
AU476437B2 (mo)
JPS4899451U (mo)
JPS491923U (mo)
JPS4984867A (mo)
JPS4889195U (mo)
CS153895B1 (mo)
CS153328B1 (mo)
CH584427A5 (mo)
CH560344A5 (mo)
CH579966A5 (mo)
CH559885A5 (mo)
CH560170A5 (mo)
CH560331A5 (mo)
CH579846A5 (mo)
CH590852A5 (mo)
CH585782A5 (mo)
CH578748A5 (mo)
CH577538A5 (mo)
CH580160A5 (mo)